In addition to advances in selective drug design and development and preclinical and clinical trials of new and repurposed pharmaceuticals the conundrum underlying the apparent opposing actions of M3R and M1R in colon cancer progression must be solved as this may reveal an entirely novel, potentially exciting therapeutic strategy [76]. This evidence concerns the gene CHRM1 and malignant colon neoplasm.